hcp.lucemyra.comOpioid Withdrawal Treatment | LUCEMYRA (lofexidine) HCP

This site is intended for U.S. Healthcare Providers. Important Safety Information Full Prescribing Information For Patients Top Bar Menu Facebook page opens in new window X-Twitter page opens in new window Sign Up LUCEMYRA (lofexidine) HCP Home Clinical Studies Mechanism of Action Dosing Safety LUCEMYRA Stories Patient Support HCP Resources Contact A Rep Home Clinical Studies Mechanism of Action Dosing Safety LUCEMYRA Stories Patient Support HCP Resources Contact A Rep Start the conversation with LUCEMYRA® LUCEMYRA is the only FDA-approved, non-controlled treatment for the relief of multiple symptoms of opioid withdrawal in adults 1 Learn More Photos within this website are actor portrayals. LUCEMYRA is an in-patient or out-patient treatment for patients experiencing: Opioid Detox Help patients mitigate withdrawal symptoms when seeking an opioid-free in-patient or out-patient treatment program. Initiation of Buprenorphine Prior to the induction of sublingual buprenorphine, ease patients through the 72-hour period of abstinence often needed to avoid precipitating withdrawal. Transition from Methadone Help alleviate withdrawal symptoms in patients discontinuing methadone prior to a buprenorphine regimen. Transition to Extended-Release Naltrexone Help mitigate withdrawal symptoms during the 7- to 14-day abstinence period for patients transitioning to extended-release naltrexone injections. Unplanned Disruptions in Treatment Help mitigate withdrawal symptoms in patients with unplanned disruption of opioid treatment when opioid-agonists are unavailable or inappropriate for the situation. After-Treatment Care Help patients who have completed a successful MAT regimen with buprenorphine or methadone and are set to experience withdrawal symptoms from final step-down off treatment. Opioid Detox Help patients mitigate withdrawal symptoms when seeking an opioid-free in-patient or out-patient treatment program. Initiation of Buprenorphine Prior to the induction of sublingual buprenorphine, ease patients through the 72-hour period of abstinence often needed to avoid precipitating withdrawal. Transition from Methadone to Buprenorphine Help alleviate withdrawal symptoms in patients discontinuing methadone prior to a buprenorphine regimen. Transition to Extended-Release Naltrexone Help mitigate withdrawal symptoms during the 7- to 14-day abstinence period for patients transitioning to extended-release naltrexone injections. Unplanned Disruptions in Treatment Help mitigate withdrawal symptoms in patients with unplanned disruption of opioid treatment when opioid-agonists are unavailable or inappropriate for the situation. After-Treatment Care Help patients who have completed a successful MAT regimen with buprenorphine or methadone and are set to experience withdrawal symptoms from final step-down off treatment. Discover how LUCEMYRA helped patients relieve the symptoms of opioid withdrawal See more stories Play Video 2020 ASAM National Practice Guideline: Recommendations for Treating Opioid Withdrawal 2 The American Society of Addiction Medicine (ASAM) recognizes two main strategies for managing opioid withdrawal: gradually tapering the dose of the current opioid(s), or using a non-opioid medication, like LUCEMYRA (lofexidine). Regarding the use of alpha-2 adrenergic agonists, the Guideline states: Lofexidine should therefore be the preferred choice for withdrawal management in an outpatient setting, where monitoring of blood pressure and management of hypotension is more difficult.” -American Society of Addiction Medicine, 2020 Learn more about the 2020 ASAM Guidelines Download LUCEMYRA® (lofexidine) [Prescribing Information]. USWM, LLC; 2020 Data on file. US WorldMeds; 2017. 7. (ASAM). National practice guideline for the treatment of opioid use disorder: 2020 focused update. 2020. https://www.asam.org/Quality-Science/quality/2020 -national-practice-guideline. Accessed July 13, 2020. EXPAND COLLAPSE Click to see full Important Safety Information & Prescribing Information Indication LUCEMYRA is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. Important Safety Information LUCEMYRA may cause hypotension, bradycardia, and syncope. Avoid using LUCEMYRA in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, chronic renal failure, or marked bradycardia. LUCEMYRA should be used with caution with any medications that decrease pulse or blood pressure to avoid the risk of excessive bradycardia and hypotension. Patients using LUCEMYRA should be monitored for symptoms related to bradycardia and orthostasis. LUCEMYRA prolongs the QT interval and should be avoided in patients with congenital long QT syndrome. Monitor ECG in patients using LUCEMYRA who have renal or hepatic impairment, known QT prolongation, metabolic disturbances, pre-existing cardiovascular disease, relevant family history, or those taking drugs known to prolong the QT interval. LUCEMYRA potentiates the depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. During and after opioid discontinuation, patients are at an increased risk of fatal overdose should they resume opioid use; patients and caregivers should be informed of this increased risk. In patients with opioid use disorder, LUCEMYRA should be used in conjunction with a comprehensive treatment program. LUCEMYRA treatment should be discontinued with gradual dose reduction. The most commonly reported adverse reactions associated with LUCEMYRA treatment (incidence ≥10% and notably more frequent than placebo) are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth. Dose adjustment of LUCEMYRA is required in patients with hepatic or renal impairment. Before prescribing, see dosage recommendation tables in Full Prescribing Information. There are no contraindications for taking LUCEMYRA. To report SUSPECTED ADVERSE REACTIONS or product complaints, contact US WorldMeds at 1-833-LUCEMYRA. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Please see full Prescribing Information and Patient Information .This website uses cookies so that we understand how you and other visitors use our website. You can learn more about the cookies we use in our privacy policy . Manage Cookies Reject All Accept All Manage consent Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on . Necessary Necessary Always Enabled Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Cookie Duration Description cookielawinfo-checkbox-analytics 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". cookielawinfo-checkbox-functional 11 months The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". cookielawinfo-checkbox-necessary 11 months This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". cookielawinfo-checkbox-others 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. cookielawinfo-checkbox-performance 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". viewed_cookie_policy 11 months The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not...